Login Register
icon_bulk_orderBulk order Acrobiosystems for English
There is no goods in the shopping cart !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Home > B7-H3


Brief Information

Name:CD276 antigen
Target Synonym:B7 homolog 3,PSEC0249,UNQ309/PRO352,B7-H3,CD276 antigen,B7H3,CD276,CD276 Molecule,Costimulatory Molecule,4Ig-B7-H3,B7RP-2
Number of Launched Drugs:0
Number of Drugs in Clinical Trials:14
Lastest Research Phase:Phase 3 Clinical


Project item Indications Research phase Cooperation demands
BDA202203 B7H3+ and PD-L1+/low cancer CMC development License-out or co-development

Product ListCompare or Buy

Part of Bioactivity data

B73-H52E2-Cell-based assay
Human FcRn Heterodimer Protein Cell_Base

Human B7-H3, His Tag (Cat. No. B73-H52E2) inhibits Anti-CD3-induced proliferation of PBMC. The EC50 for this effect is 2.24-3.36 μg/mL (Routinely tested).

Cynomolgus B7-H3, His TagCynomolgus B7-H3, His Tag (Cat. No. B73-C52Ha) ELISA bioactivity

Immobilized Cynomolgus B7-H3, His Tag (Cat. No. B73-C52Ha) at 2 μg/mL (100 μL/well) can bind Monoclonal Anti-Human B7-H3 / B7-H3 (4Ig) Antibody, Human IgG1 with a linear range of 0.1-4 ng/mL (QC tested).

Cynomolgus B7-H3, His Tag (Cat. No. ) MALS images

The purity of Cynomolgus B7-H3, His Tag (Cat. No. B73-C52Ha) is more than 90% and the molecular weight of this protein is around 65-85 kDa verified by SEC-MALS.

Cynomolgus B7-H3, His TagCynomolgus B7-H3, His Tag (Cat. No. B73-C52Ha) ELISA bioactivity

Immobilized Cynomolgus B7-H3, His Tag (Cat. No. B73-C52Ha) at 2 μg/mL (100 μL/well) can bind Monoclonal Anti-Human B7-H3 / B7-H3 (4Ig) Antibody, Human IgG1 with a linear range of 0.1-4 ng/mL (QC tested).

Synonym Name

B7-H3,CD276,B7 homolog 3


B7 homolog 3 (B7-H3), a member of the immunoglobulin superfamily, is also known CD276, which contains two Ig-like C2-type (immunoglobulin-like) domains and two Ig-like V-type (immunoglobulin-like) domains. B7-H3 may participate in the regulation of T-cell-mediated immune response. B7-H3 also plays a protective role in tumor cells by inhibiting natural-killer mediated cell lysis as well as a role of marker for detection of neuroblastoma cells. Furthermore, B7-H3 is involved in the development of acute and chronic transplant rejection and in the regulation of lymphocytic activity at mucosal surfaces. It could also play a key role in providing the placenta and fetus with a suitable immunological environment throughout pregnancy.

Clinical and Translational Updates

Clinical Drug Information

Name Research Code Research Phase Company Indications Clinical Trials
Monoclonal antibody 8H9 I-124 124I-8H9; 124I-8H9-(B7-H3) Phase 2 Clinical Memorial Sloan Kettering Cancer Center Glioma Details
SCRI-CARB7H3 SCRI-CARB7H3 Phase 1 Clinical Seattle Children'S Hospital Central Nervous System Neoplasms; Glioma Details
4SCAR-276 4SCAR-276 Phase 2 Clinical Shenzhen Geno-Immune Medical Institute Neoplasms Details
CD-276-targeted Chimeric Antigen Receptor T Cell Therapy CD276 CAR-T Phase 2 Clinical Shenzhen University General Hospital Pancreatic Neoplasms Details
Enoblituzumab MGA-271; TJ271 Phase 2 Clinical Macrogenics Head and Neck Neoplasms; Rhabdomyosarcoma; Solid tumours; Squamous Cell Carcinoma of Head and Neck; Desmoplastic Small Round Cell Tumor; Carcinoma, Renal Cell; Wilms Tumor; Triple Negative Breast Neoplasms; Urinary Bladder Neoplasms; Prostatic Neoplasms; Urethral Neoplasms; Osteosarcoma; Sarcoma, Ewing; Neuroblastoma; Melanoma; Carcinoma, Non-Small-Cell Lung Details
MGC-018 MGC-018 Phase 2 Clinical Macrogenics Neoplasms Details
Monoclonal antibody 8H9 I-131 8H9-MAb; 131-I-8H9; 131I-8H9-(B7-H3) Phase 3 Clinical Memorial Sloan Kettering Cancer Center Neuroblastoma; Peritoneal Neoplasms; Central Nervous System Diseases; Neoplasm Metastasis Details
B7-H3 CAR-T cell therapy (Zhejiang University) Phase 2 Clinical Zhejiang University Alumni Association (Singapore) Glioblastoma Details
Obrindatamab MGD-009; B7-H3 x CD3 Phase 2 Clinical Macrogenics Sarcoma, Synovial; Carcinoma, Non-Small-Cell Lung; Melanoma; Thyroid Neoplasms; Neuroblastoma; Neurofibrosarcoma; Sarcoma; Prostatic Neoplasms; Breast Neoplasms; Ovarian Neoplasms; Urinary Bladder Neoplasms; Mesothelioma; Wilms Tumor; Pancreatic Neoplasms; Colonic Neoplasms; Squamous Cell Carcinoma of Head and Neck; Carcinoma, Renal Cell; Rhabdomyosarcoma Details
DS-7300 DS-7300 Phase 2 Clinical Daiichi Sankyo Co Ltd Solid tumours Details
Anti-CD276 CAR T-cell therapy (Persongen ) Phase 1 Clinical Persongen Biotherapeutics (Suzhou) Co Ltd Stomach Neoplasms; Osteosarcoma; Neuroblastoma; Lung Neoplasms Details
Mirzotamab clezutoclax ABBV-155 Phase 1 Clinical Abbvie Inc Hematologic Neoplasms; Solid tumours Details
Fully Human B7H3 CAR-T Cells Therapy fhB7H3.CAR-Ts Phase 2 Clinical The Affiliated Hospital Of Xuzhou Medical University Ovarian Neoplasms Details
Omburtamab I-131 Phase 1 Clinical Y-Mabs Central Nervous System Neoplasms; Sarcoma; Neuroblastoma; Brain Neoplasms; Diffuse Intrinsic Pontine Glioma Details
177Lu-DTPA-omburtamab Phase 2 Clinical Y-Mabs Solid tumours; Meningeal Neoplasms Details
B7-H3-targeting CAR-T cell therapy (Beijing Tiantan Hospital, Capital Medical University) Beijing Tiantan Hospital, Capital Medical University Details

This web search service is supported by Google Inc.

Call us
Call us
North America: +1 800-810-0816 (Toll Free)
Asia & Pacific: +86 400-682-2521
+1 888-377-6111
1 Innovation Way, Newark, DE 19711, USA

Leave a message